Opinion

Video

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

Author(s):

Joshua K. Sabari, MD,Edward B. Garon, MD, MS

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

Related Videos
Alec Watson, MD
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Balazs Halmos, MD
Balazs Halmos, MD
2 experts in this video
2 experts in this video
Related Content
Lung Cancer | stock.adobe.com
December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

FDA
December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 17th 2024

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

NRG1 Fusions in Lung Cancer | Image Credit: © catalin – stock.adobe.com
December 17th 2024

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers